Centessa announces FDA clearance of IND to initiate Phase 1/2a study of LB101

Centessa Pharmaceuticals announced that it has received clearance of its Investigational New Drug, IND, application from the U.S. Food and Drug Administration, FDA, to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors. LB101 is the first product candidate developed using the Company’s proprietary LockBody technology. "We are very excited to be bringing our first LockBody candidate to the clinic and to be advancing a potentially transformative technology for patients with solid tumors," said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. "The clearance of our IND for LB101 is an important milestone for our company as we have an ambitious strategy to advance multiple potential LockBody candidates in areas where there is a significant need for new cancer treatment options. We look forward to initiating the Phase 1/2a trial of LB101 as soon as possible."